News

Cascades Inc. Reveals Q4 2024 Performance Insights

Cascades Inc. Reveals Q4 2024 Performance Insights

Cascades Inc. Reports Q4 and Full Year 2024 Results

Cascades Inc. (TSX: CAS) recently shared its financial performance for the fourth quarter and full year of 2024. In the latest report, the company displayed noteworthy trends and changes that culminated in their recent quarterly outcomes.

Key Q4 2024 Highlights

The financial highlights for the fourth quarter show a sales increase to $1,211 million, compared to $1,201 million in the previous quarter and $1,138 million in the same quarter last year. Operating income saw a dip to $16 million from $36 million in Q3, showcasing the challenges faced within the period.

Net Loss Per Share

The net loss per share for this quarter was $(0.13), which is an improvement from the $(0.57) recorded in Q4 2023. Adjusted EBITDA surged to $146 million from $122 million, indicating healthy performance despite facing operational costs.

Annual Performance for 2024

For the fiscal year ending December 31, 2024, Cascades reported total annual sales of $4,701 million, marking a slight increase from 2023's $4,638 million. Operating income dramatically rose to $95 million, compared to $40 million of the previous year.

Debt Levels and Future Investments

The company also noted an increase in net debt to $2,096 million against $1,882 million last year. The ratio of net debt to EBITDA stands at 4.2x, up from 3.4x, reflecting on their financial strategy moving forward. Cascades plans capital expenditures to be roughly $175 million as they continue to enhance their capabilities for future growth.

Insights from the CEO

Hugues Simon, the President and CEO, acknowledged the quarter's performance by linking it to favorable selling prices and operating costs associated with their Containerboard sector. These factors played a significant role in their results, despite the challenges posed by seasonal volume drops.

Long-Term Strategy Amid Challenges

Looking ahead, Mr. Simon emphasizes the importance of navigating potential uncertainties due to market conditions, particularly regarding bilateral tariffs impacting cross-border sales. The company is taking proactive measures to mitigate these risks, ensuring solid strategies are in place and focusing on innovation and efficiency improvements.

Commitment to Sustainability

Cascades is dedicated to sustainable practices in their operations, showcasing their commitment to excellence and responsible business models. Ongoing initiatives include enhancing health and safety standards and improving service levels across their diverse product offerings.

Financial Summary Table Overview

In the detailed financial summary table, key metrics include:

  • Quarterly Sales: 1,211 million CAD
  • Operating Income: 16 million CAD
  • Net Loss: (13) million CAD
  • Adjusted EBITDA: 146 million CAD

Cascades will continue to enhance its operational strategies, keeping stakeholders updated as they strive toward growth and recovery in future quarters.

Frequently Asked Questions

What were the main highlights from Cascades' Q4 2024 report?

Sales reached $1,211 million, with an operating income of $16 million and an adjusted EBITDA of $146 million.

How did Cascades perform in fiscal year 2024 compared to 2023?

Annual sales were $4,701 million in 2024, up from $4,638 million in 2023, with operating income increasing from $40 million to $95 million.

What changes were seen in Cascades' net debt?

Net debt increased to $2,096 million, compared to $1,882 million as of the previous year, indicating a focus on managing liquidity amidst growth strategies.

How is Cascades addressing potential market challenges?

The company is proactively implementing strategies to mitigate risks linked to tariffs and market uncertainties.

What is Cascades' future outlook?

Future strategies will focus on efficiency, sustainability, and maintaining their position as a preferred supplier in the packaging sector.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 55

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading

Top 5 Most Recently Viewed Articles

Regulatory T-Cells Market Growth Driven by New Therapies

Updated Category News Views 217

Insights into the Regulatory T-Cells Market Growth The landscape of the Treg therapy market is rapidly evolving as companies globally actively develop innovative regulatory T-cell therapies to treat various critical conditions. These include systemic lupus erythematosus (SLE), lupus nephritis, atopic dermatitis, rheumatoid arthritis, psoriasis, progressive multiple...

Continue Reading
Natural Grocers Unveils Autumnfest Super Savings Event

Updated Category News Views 67

Natural Grocers Introduces Autumnfest Savings Event As the autumn leaves begin to fall, Natural Grocers invites shoppers to revel in the festivities of the season with their exciting Autumnfest Savings Event. This annual celebration promises customers an incredible opportunity to enjoy significant discounts, free samples, and delightful seasonal recipes. With savings of...

Continue Reading
Anthem Blue Cross Commits $10 Million for Wildfire Relief

Updated Category News Views 270

Anthem Blue Cross Generously Assists Communities Affected by Wildfires For over eight decades, Anthem Blue Cross has maintained a strong presence in California, prioritizing the health and well-being of its residents. Our focus has always been on putting people first, as we acknowledge the struggles that come with disasters that can significantly impact the lives of our...

Continue Reading
Corporate Legal Departments Face Major Workforce Challenges

Updated Category News Views 179

Corporate Legal Departments Face Major Workforce Challenges In the evolving landscape of corporate legal departments, a significant wave of attrition is looming as in-house attorneys express a desire to seek better opportunities. The increase in workloads, coupled with concerns about artificial intelligence and limited career advancement prospects, has prompted many legal...

Continue Reading
Currax Achieves FDA Approval for Enhanced CONTRAVE Supply Chain

Updated Category News Views 411

Currax Expands Manufacturing Capabilities for CONTRAVE Currax Pharmaceuticals LLC, a focused specialty pharmaceutical company, recently announced a significant milestone in its operations. The U.S. Food and Drug Administration (FDA) has granted approval for a second manufacturing facility dedicated to the production of CONTRAVE (naltrexone HCl/bupropion HCl), a leading...

Continue Reading